Oncology

News
Ojemda

Ipsen builds again, licensing Day One glioma drug

Ipsen has signed yet another portfolio-expanding deal – its fifth of the year so far – claiming rights outside the US to a drug for common brain cancer glioma from Day One Biopharmaceutical

Oncology
Video interview with Matteo Levisetti

ASCO 2024 - Matteo Levisetti

ASCO 2024 marked the 10th anniversary of checkpoint inhibitors, which powerfully changed the nature of cancer immunotherapy.

News
GSK files Blenrep in EU, seeking return to market

GSK files Blenrep in EU, seeking return to market

Less than two years after pulling multiple myeloma therapy Blenrep off most markets around the world, GSK has filed for approval of the drug in the EU once again, hoping to restore its bloc